Calamos Advisors’s Pfizer PFE Stock Holding History

Calamos Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-969,680	Closed	-$39.1M	–	771
2019 Q1	$39.1M	Buy	+969,680	New	+$38.8M	0.24%	126

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Calamos Advisors's PFE Position: Q2 2026 in Review

Calamos Advisors reduced its Pfizer (PFE) stake by 2.9% in Q2 2026, selling an estimated $1.36M and leaving 1,753,548 shares worth $42.2M. The position accounts for 0.14% of the portfolio, ranked #152.

Calamos Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $146M in Q2 2019. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Calamos Advisors held 1,753,548 shares of Pfizer worth $42.2M as of Q2 2026.
Calamos Advisors sold 52,111 Pfizer shares in Q2 2026, an estimated $1.36M.
Pfizer made up 0.14% of Calamos Advisors's portfolio in Q2 2026, its #152 holding.
Calamos Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Calamos Advisors's Pfizer position peaked at $146M in Q2 2019.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.